This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Draft guideline on the clinical investigation of medicinal products in the treat...
Minutes of the CAT meeting 22-24 January 2025
Union product database: webinar for veterinary marketing authorisation holders o...
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mR...
Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime...
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Va...
Human medicines European public assessment report (EPAR): mResvia, Single-strand...
Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, ...
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, D...
Human medicines European public assessment report (EPAR): Remicade, infliximab, ...
Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib,...
Human medicines European public assessment report (EPAR): Welireg, belzutifan, S...
Guidance on the details of the classification of variations requiring assessment...
Infographic - Orphan Medicines in the EU
Human medicines European public assessment report (EPAR): Soliris, eculizumab, D...
Human medicines European public assessment report (EPAR): Spinraza, nusinersen, ...
Human medicines European public assessment report (EPAR): Xalkori, crizotinib, D...
Addendum to the Guideline on clinical development of vaccines to address clinica...
Clinical Trial Information System (CTIS) evaluation timelines
Clinical evaluation of new vaccines - Scientific guideline
Human medicines European public assessment report (EPAR): Voydeya, Danicopan, Da...
Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, D...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,...